Johnson & Johnson (JNJ) has been a rewarding stock to hold, up about 53% over the past year against about 17% for the S&P 500. The change worth noticing over that stretch is quieter than the price. Management said sales still rose 5.6% despite a STELARA drag of about 460 basis points. Management is encouraging investors to evaluate the company's underlying momentum by presenting growth rates that exclude STELARA alongside its reported figures.
A year and a half ago, that drag was the headline. Management's own framing of the first quarter of 2025 noted an approximate 810 basis point headwind on Innovative Medicine sales.
By the second quarter of 2026, that segment-level drag remained heavy at roughly 760 basis points (or about 460 basis points across the total enterprise), yet management's emphasis shifted to highlighting double-digit operational growth excluding STELARA
The exclusion is not a rounding adjustment. STELARA sales fell 55.7% in the second quarter of 2026, and management put that drag at about 460 basis points of the whole company's 5.6% operational sales growth.
Two products show what the replacement looks like. TREMFYA booked $2 billion of sales in the second quarter of 2026, up over 70%, and management says ulcerative colitis and Crohn's disease are the major drivers of that growth. ICOTYDE, a recently launched once-daily pill for psoriasis, is the second, which leadership has highlighted as a key pipeline priority for the immunology business.
#sales #basis #drag #quarter
A year and a half ago, that drag was the headline. Management's own framing of the first quarter of 2025 noted an approximate 810 basis point headwind on Innovative Medicine sales.
By the second quarter of 2026, that segment-level drag remained heavy at roughly 760 basis points (or about 460 basis points across the total enterprise), yet management's emphasis shifted to highlighting double-digit operational growth excluding STELARA
The exclusion is not a rounding adjustment. STELARA sales fell 55.7% in the second quarter of 2026, and management put that drag at about 460 basis points of the whole company's 5.6% operational sales growth.
Two products show what the replacement looks like. TREMFYA booked $2 billion of sales in the second quarter of 2026, up over 70%, and management says ulcerative colitis and Crohn's disease are the major drivers of that growth. ICOTYDE, a recently launched once-daily pill for psoriasis, is the second, which leadership has highlighted as a key pipeline priority for the immunology business.
#sales #basis #drag #quarter
2 months ago
